M.D., Co-Founder & CEO, PathAI
Andy earned his MD from Brown Medical School and completed residency and fellowship training in Anatomic Pathology and Molecular Genetic Pathology from Stanford University. He completed a PhD in Biomedical Informatics from Stanford University, where he developed one of the first machine-learning based systems for cancer pathology. He is board certified by the American Board of Pathology in Anatomic Pathology and Molecular Genetic Pathology. Prior to co-founding PathAI, he was on the faculty of Harvard Medical School in the Department of Pathology at Beth Israel Deaconess Medical Center. He has published over 110 papers in the fields of cancer biology, cancer pathology, and biomedical informatics.
Presentation Title and Company Description
AI and Data Science Showcase: Artificial Intelligence for Precision Cancer Pathology
PathAI, formed in 2016 in Cambridge, MA, is the world’s leading computational pathology company. We use artificial intelligence to improve the health of people around the world by enhancing the predictive power of pathologic diagnoses and accelerating the development of novel therapies. We serve partners in the pharmaceutical industry, in the clinical laboratory, and in global health.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: The field of AI and machine learning is undergoing explosive development and growth, yet the timing of impact in the area of health care and health management as a key element in the clinical care is still uncertain. How AI will influence our approaches to the management of complex diseases such as cancer, what elements of technologies will come into play, and how this be impacted in a regulated setting remains to be seen. Clearly, we will see many rewards with AI in the clinic, but we first must anticipate the hurdles along to way and devise solutions to overcome them.